Dr. Dean A. Delmastro
Claim this profileMarshfield Medical Center-Marshfield
Area of expertise
Cancer
Dean A. Delmastro has run 4 trials for Cancer. Some of their research focus areas include:
Breast Cancer
Dean A. Delmastro has run 2 trials for Breast Cancer. Some of their research focus areas include:
Affiliated Hospitals
Marshfield Medical Center-Marshfield
Marshfield Medical Center-EC Cancer Center
Clinical Trials Dean A. Delmastro is currently running
Durvalumab + Chemotherapy
for Breast Cancer
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 negative breast cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as paclitaxel, doxorubicin, and cyclophosphamide work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. There is some evidence from previous clinical trials that people who have a MammaPrint High 2 Risk result may be more likely to respond to chemotherapy and immunotherapy. Adding durvalumab to usual chemotherapy may be able to prevent the cancer from returning for patients with MP2 stage II-III hormone receptor positive, HER2 negative breast cancer.
Recruiting
2 awards
Phase 3
40 criteria
Targeted Therapy vs. Chemotherapy
for Thyroid Cancer
This phase III trial compares the effect of cabozantinib versus combination dabrafenib and trametinib for the treatment of patients with differentiated thyroid cancer that does not respond to treatment (refractory) and which expresses a BRAF V600E mutation. Cabozantinib is in a class of medications called receptor tyrosine kinase inhibitors. It binds to and blocks the action of several enzymes which are often over-expressed in a variety of tumor cell types. This may help stop or slow the growth of tumor cells and blood vessels the tumor needs to survive. Dabrafenib is an enzyme inhibitor that binds to and inhibits the activity of a protein called B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. Trametinib is also an enzyme inhibitor. It binds to and inhibits the activity of proteins called MEK 1 and 2, which play a key role in activating pathways that regulate cell growth. This may inhibit the growth of tumor cells mediated by these pathways. The usual approach for patients with thyroid cancer is targeted therapy with dabrafenib and trametinib. This trial may help researchers decide which treatment option (cabozantinib alone or dabrafenib in combination with trametinib) is safer and/or more effective in treating patients with refractory BRAF V600E-mutated differentiated thyroid cancer.
Recruiting
2 awards
Phase 3
7 criteria
More about Dean A. Delmastro
Clinical Trial Related
4 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Dean A. Delmastro has experience with
- Cisplatin
- Atezolizumab
- Cabozantinib S-malate
- Gemcitabine Hydrochloride
- Carboplatin
- Etoposide
Breakdown of trials Dean A. Delmastro has run
Cancer
Breast Cancer
Breast cancer
Islet Cell Tumor
Neuroendocrine Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Dean A. Delmastro specialize in?
Dean A. Delmastro focuses on Cancer and Breast Cancer. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are Stage III.
Is Dean A. Delmastro currently recruiting for clinical trials?
Yes, Dean A. Delmastro is currently recruiting for 2 clinical trials in Marshfield Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Dean A. Delmastro has studied deeply?
Yes, Dean A. Delmastro has studied treatments such as Cisplatin, Atezolizumab, Cabozantinib S-malate.
What is the best way to schedule an appointment with Dean A. Delmastro?
Apply for one of the trials that Dean A. Delmastro is conducting.
What is the office address of Dean A. Delmastro?
The office of Dean A. Delmastro is located at: Marshfield Medical Center-Marshfield, Marshfield, Wisconsin 54449 United States. This is the address for their practice at the Marshfield Medical Center-Marshfield.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.